|
model 1
|
model 2
|
model 3
|
---|
β
|
95% CI
|
P value
|
β
|
95% CI
|
P value
|
β
|
95% CI
|
P value
|
---|
Change of baPWV (cm/s)
|
TyG (continuous)
|
32.034
|
4.642–59.425
|
0.022
|
57.119
|
22.835–91.402
|
0.001
|
149.582
|
90.823–208.342
|
< 0.001
|
Quartile 2 (ref: quartile 1)
|
59.745
|
10.509–108.982
|
0.017
|
61.086
|
12.582–109.59
|
0.014
|
76.297
|
28.63–123.964
|
0.002
|
Quartile 3
|
85.613
|
36.416–134.81
|
0.001
|
93.631
|
43.889–143.373
|
< 0.001
|
102.562
|
52.08–153.044
|
< 0.001
|
Quartile 4
|
74.957
|
25.494–124.42
|
0.003
|
98.555
|
37.584–159.526
|
0.002
|
129.525
|
58.723–200.326
|
< 0.001
|
P for trend
| | |
0.002
| | |
< 0.001
| | |
< 0.001
|
Change rate of baPWV (cm/s/year)
|
TyG (continuous)
|
11.892
|
3.415–20.368
|
0.006
|
17.974
|
7.307–28.642
|
0.001
|
40.372
|
21.853–58.891
|
< 0.001
|
Quartile 2 (ref: quartile 1)
|
11.870
|
-3.385–27.125
|
0.127
|
12.122
|
-2.986–27.229
|
0.116
|
16.529
|
1.507–31.551
|
0.031
|
Quartile 3
|
20.615
|
5.373–35.858
|
0.008
|
22.642
|
7.149–38.135
|
0.004
|
24.390
|
8.481–40.299
|
0.003
|
Quartile 4
|
24.616
|
9.291–39.941
|
0.002
|
30.750
|
11.76–49.741
|
0.002
|
37.607
|
15.294–59.919
|
0.001
|
P for trend
| | |
0.001
| | |
0.001
| | |
< 0.001
|
Slope of baPWV
|
TyG (continuous)
|
9.570
|
1.538–17.601
|
0.020
|
14.238
|
4.121–24.355
|
0.006
|
34.874
|
17.238–52.51
|
< 0.001
|
Quartile 2 (ref: quartile 1)
|
10.986
|
-3.469–25.441
|
0.136
|
10.888
|
-3.439–25.215
|
0.137
|
14.872
|
0.57–29.175
|
0.042
|
Quartile 3
|
18.739
|
4.296–33.182
|
0.011
|
20.092
|
5.399–34.785
|
0.007
|
22.163
|
7.016–37.31
|
0.004
|
Quartile 4
|
20.126
|
5.604–34.647
|
0.007
|
23.648
|
5.639–41.658
|
0.010
|
30.576
|
9.332–51.82
|
0.005
|
P for trend
| | |
0.004
| | |
0.003
| | |
0.002
|
- Model 1: Adjusted age and sex; Model 2: Age, sex, BMI, smoking status, drinking status, physical activity, diabetes, dyslipidaemia, baPWV at baseline, and MAP at baseline and follow-up; Model 3: Model 2 plus FBG, triglyceride, PBG, LDL-C, eGFR, uric acid, homocysteine, and use of antidiabetic, lipid-lowering, or antihypertensive medications at baseline and follow-up